Where do GLP-1 drugs fit in sleep apnea care?

Clinical takeaway: Consider GLP-1 receptor agonists, particularly tirzepatide, as an adjunctive treatment option for patients with obesity-related obstructive sleep apnea (OSA), while continuing to view CPAP as the standard of care.

OSA affects nearly 1 billion adults worldwide and is strongly linked to cardiovascular disease, stroke, and mortality. Although CPAP remains the most effective therapy, real-world adherence is often poor, and obesity, present in 60% to 70% of patients with OSA, is the condition’s most important modifiable risk factor.

In this review, investigators examined the rapidly evolving evidence for GLP-1 RAs in OSA, a field transformed by the FDA approval of tirzepatide in 2024 as the first medication specifically indicated for moderate-to-severe OSA in adults with obesity.

Across six meta-analyses, GLP-1 RAs consistently reduced apnea-hypopnea index (AHI) scores, with improvements ranging from roughly 6 to 22 events per hour. The strongest evidence came from the phase 3 SURMOUNT-OSA trials, in which tirzepatide reduced AHI by approximately 20 to 24 events per hour compared with placebo. Notably, 42% to 50% of treated patients achieved disease remission, defined as either an AHI below 5 events per hour or below 15 events per hour without symptoms.

The review attributes much of this benefit to weight loss and reductions in tongue fat and parapharyngeal adipose tissue, both of which contribute to upper-airway collapse during sleep. The authors also describe emerging evidence that GLP-1 RAs may have weight-independent effects through modulation of chemosensitivity, upper-airway neuromuscular control, and inflammatory pathways, though these mechanisms remain investigational.

Despite the promise of pharmacotherapy, the authors caution that GLP-1 RAs do not yet match the efficacy of CPAP, cardiovascular outcome benefits remain unproven, and weight regain after discontinuation remains a challenge. They suggest the drugs are best positioned as complementary therapy alongside CPAP, as a tool for preoperative optimization before upper-airway surgery, or potentially to broaden eligibility for hypoglossal nerve stimulation.

“Our review suggests that GLP-1 receptor agonists offer a disease-modifying adjunct for obesity-related OSA, best positioned as complementary therapy rather than a replacement for established treatments,” the authors concluded.

Source: Harris A, Kaffenberger T. (2026 Sep 3) JAMA Otolaryngol Head Neck Surg. Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review